Tricida (TCDA) Misses Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
CORRECTING and REPLACING -- Tricida Announces First Quarter 2021 Financial Results
May 6, 2021 5:07 PM EDTSOUTH SAN FRANCISCO, May 06, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, May 6th by Tricida, Inc. (Nasdaq: TCDA), please note that the first and second bullets of the "Upcoming Milestones" should have been combined into one bullet. The corrected release follows:
Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis and slow CKD progression in patients with chronic kidney disease (CKD),... More
